摘要
该文研究了灵芝复合剂乙酸乙酯提取物(Ganoderma lucidum Complex Ethyl Acetate Extract,GCE)的化学组成及抗肿瘤活性.GCE由灵芝、菟丝子、五味子、党参(质量比 50.3:25.2:15.7:8.8)组成复合剂后再经乙酸乙酯萃取所得.试验采用超高压液相色谱飞行时间质谱联用仪(UPLC-Q-TOF-MS)分析其物质组成;设空白组、模型组、阳性对照组、GCE低、中、高剂量组.检测其抑瘤率,脏器指数,脾淋巴细胞增殖能力,血清细胞因子.结果表明:GCE主要由 11 种化合物组成:L-焦谷氨酸、DL-亮氨酸腺苷、D-赤酮酸内酯、L-正亮氨酸、邻苯三酚、2-羟基-3-甲基吡喃-4-酮、绿原酸、3-(3,4,5-三甲氧基苯基)丙酸、槲皮素、五味子素;GCE低、中、高剂量组(50、100、200 mg/kg)H22 荷瘤小鼠的抑瘤率分别为 35.14%、38.25%、50.87%;与模型组相比,GCE低、中、高剂量均能显著促进小鼠脾淋巴细胞的增殖(P<0.01);GCE高剂量能显著促进小鼠的IL-6、TNF-α和IL-12分泌(P<0.05).结论,GCE对H22荷瘤小鼠肿瘤有一定抑制作用,该研究结果可为抗肿瘤功能的产品研发提供新思路.
Abstract
The chemical composition and antitumor activity of ethyl acetate extracts from Ganoderma lucidum compounds(GCE)were investigated.GCE was extracted using ethyl acetate from compounds of Ganoderma lucidum,Cuscuta chinensis Lam,Schisandra chinensis,and Codonopsis pilosula(at a mass ratio of 50.3:25.2:15.7:8.8).Ultra-high pressure liquid chromatography coupled with time-of-flight mass spectrometry(UPLC-Q-TOF-MS)was used to analyze its composition.Blank,model,positive control,and GCE-treated groups(low,medium,and high dosages)were established.The tumor inhibition rate,organ index,splenic lymphocyte proliferation capacity,and serum cytokine levels were measured.The results showed that GCE is mainly composed of 11 compounds:L-pyroglutamic acid,DL-leucine adenosine,D-erythronolactone,L-norleucine,pyrogallol,2-hydroxy-3-methylpyran-4-one,chlorogenic acid,3-(3,4,5-trimethoxyphenyl)propionic acid,quercetin,and schisandrin.The tumor inhibition rates of H22 tumor-bearing mice in low-,medium-,and high-dose GCE-treated groups(at 50,100 and 200 mg/kg)H22 were 35.14%,38.25%,and 50.87%,respectively.Comparison of the model and treated groups revealed that low-,medium-,and high-dose GCE significantly promoted the proliferation of splenic lymphocytes(P<0.01).A high dose of GCE could significantly promote the secretion of IL-6,TNF-α,and IL-12 in mice(P<0.05).In short,GCE has certain inhibitory effects on the tumor of H22 tumor-bearing mice.The results of this study can provide insights into the development of antitumor products.
基金项目
广东省自然科学基金面上项目(2020A1515010371)
维普
万方数据